On the public citation graph
Characterizing the outcomes of metastatic papillary renal cell carcinoma
0 signed · 76 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/cncr.24864openalex-snapshot
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America
inferredcites →https://doi.org/10.1002/cncr.28151openalex-snapshot
Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria
inferredcites →https://doi.org/10.1007/bf02524349openalex-snapshot
Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma
inferredcites →https://doi.org/10.1007/s10637-010-9491-6openalex-snapshot
Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma
inferredcites →https://doi.org/10.1007/s12032-009-9177-0openalex-snapshot
Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies
inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
inferredcites →https://doi.org/10.1016/j.eururo.2014.04.029openalex-snapshot
Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity
inferredcites →https://doi.org/10.1016/j.eururo.2014.05.010openalex-snapshot
Systemic Therapy for Non–clear Cell Renal Cell Carcinomas: A Systematic Review and Meta-analysis
inferredcites →https://doi.org/10.1016/j.eururo.2015.10.049openalex-snapshot
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non–Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial
inferredcites →https://doi.org/10.1016/j.juro.2009.07.019openalex-snapshot
Prognostic Impact of Histological Subtype on Surgically Treated Localized Renal Cell Carcinoma
inferredcites →https://doi.org/10.1016/j.juro.2009.12.035openalex-snapshot
Histological Subtype is an Independent Predictor of Outcome for Patients With Renal Cell Carcinoma
inferredcites →https://doi.org/10.1016/j.urology.2006.09.052openalex-snapshot
Survival Analysis of 130 Patients with Papillary Renal Cell Carcinoma: Prognostic Utility of Type 1 and Type 2 Subclassification
inferredcites →https://doi.org/10.1016/s0022-5347(18)30885-1openalex-snapshot
645: Survival Analysis of 130 Patients with Papillary Renal Cell Carcinoma. Prognostic Utility of Type 1 and Type 2 Sub Classification
inferredcites →https://doi.org/10.1016/s0959-8049(14)70521-0openalex-snapshot
395 cMet: Proof-of-concept clinical trial with volitinib in patients with advanced papillary renal cell cancer (PRCC)
inferredcites →https://doi.org/10.1016/s1470openalex-snapshot
Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study
inferredcites →https://doi.org/10.1016/s1470-2045(09)70162-7openalex-snapshot
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
inferredcites →https://doi.org/10.1016/s1470-2045(15)00515-xopenalex-snapshot
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
inferredcites →https://doi.org/10.1016/s1470-2045(16)30107-3openalex-snapshot
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
inferredcites →https://doi.org/10.1056/nejmoa1505917openalex-snapshot
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
inferredcites →https://doi.org/10.1093/annonc/mdr586openalex-snapshot
Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma
inferredcites →https://doi.org/10.1093/annonc/mds582openalex-snapshot
Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma
inferredcites →https://doi.org/10.1093/annonc/mdt578openalex-snapshot
Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies
inferredcites →https://doi.org/10.1093/annonc/mdu445openalex-snapshot
PD-L1 expression in nonclear-cell renal cell carcinoma
inferredcites →https://doi.org/10.1093/annonc/mdv149openalex-snapshot
First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)
inferredcites →https://doi.org/10.1097/00000478-200305000-00005openalex-snapshot
Comparisons of Outcome and Prognostic Features Among Histologic Subtypes of Renal Cell Carcinoma
inferredcites →https://doi.org/10.1097/01.ju.0000081122.57148.ecopenalex-snapshot
Prognostic Factors for the Survival of Patients with Papillary Renal Cell Carcinoma: Meaning of Histological Typing and Multifocality
inferredcites →https://doi.org/10.1158/1078-0432.ccr-08-1229openalex-snapshot
Cytogenetic and Molecular Tumor Profiling for Type 1 and Type 2 Papillary Renal Cell Carcinoma
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-2173openalex-snapshot
MET Is a Potential Target across All Papillary Renal Cell Carcinomas: Result from a Large Molecular Study of pRCC with CGH Array and Matching Gene Expression Array
inferredcites →https://doi.org/10.1200/jco.2002.11.123openalex-snapshot
Treatment Outcome and Survival Associated With Metastatic Renal Cell Carcinoma of Non–Clear-Cell Histology
inferredcites →https://doi.org/10.1200/jco.2005.07.055openalex-snapshot
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
inferredcites →https://doi.org/10.1200/jco.2007.13.3223openalex-snapshot
Efficacy of Sunitinib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma
inferredcites →https://doi.org/10.1200/jco.2008.21.4809openalex-snapshot
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
inferredcites →https://doi.org/10.1200/jco.2012.43.3383openalex-snapshot
Phase II and Biomarker Study of the Dual MET/VEGFR2 Inhibitor Foretinib in Patients With Papillary Renal Cell Carcinoma
inferredcites →https://doi.org/10.1200/jco.2014.32.4_suppl.410openalex-snapshot
Open-label, phase II raptor study of everolimus (EVE) for papillary mRCC: Efficacy in type 1 and type 2 histology.
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4887475openalex-extracted
Bioinformatics Analysis Highlights GABRD as a Potential Prognostic Biomarker and Therapeutic Target in Kidney Renal Papillary Cell Carcinoma
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.21869openalex-snapshot
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival
inferred← citeshttps://doi.org/10.1002/cam4.3563openalex-snapshot
Comprehensive subgroup analyses of survival outcomes between clear cell renal cell adenocarcinoma and papillary renal cell adenocarcinoma
inferred← citeshttps://doi.org/10.1002/iju5.12035openalex-snapshot
Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
inferred← citeshttps://doi.org/10.1007/s00345-020-03187-yopenalex-snapshot
Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis
inferred← citeshttps://doi.org/10.1007/s12094-019-02181-0openalex-snapshot
Prognostic factors for the survival of patients with papillary renal cell carcinoma after surgical management
inferred← citeshttps://doi.org/10.1016/j.canlet.2020.06.016openalex-snapshot
Polycystin-1 induces activation of the PI3K/AKT/mTOR pathway and promotes angiogenesis in renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.clgc.2022.03.004openalex-snapshot
Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary Renal Cell Carcinoma: Results from the INternational Marker Consortium for Renal Cancer (INMARC) Cohort
inferred← citeshttps://doi.org/10.1016/j.ctarc.2022.100639openalex-snapshot
Advanced papillary renal cell carcinoma: Epidemiology, genomic drivers, current therapies, and ongoing trials
inferred← citeshttps://doi.org/10.1016/j.ctrv.2021.102228openalex-snapshot
Checkpoint inhibitors in metastatic papillary renal cell carcinoma
inferred← citeshttps://doi.org/10.1016/j.ejca.2020.02.001openalex-snapshot
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial
inferred← citeshttps://doi.org/10.1016/j.ejca.2021.08.046openalex-snapshot
Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d’Etude des Tumeurs Uro-Génitales)
inferred← citeshttps://doi.org/10.1016/j.euo.2019.03.007openalex-snapshot
Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium
inferred← citeshttps://doi.org/10.1016/j.euo.2020.01.001openalex-snapshot
Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome—Results from the International Metastatic Renal Cell Carcinoma Database Consortium
inferred← citeshttps://doi.org/10.1016/j.jvir.2023.09.035openalex-snapshot
Locoregional Therapies in Immunologically “Cold” Tumors: Opportunities and Clinical Trial Design Considerations
inferred← citeshttps://doi.org/10.1016/j.urology.2021.12.022openalex-snapshot
Disparities in Cancer Specific and Overall Survival Outcomes in African Americans With Renal Cell Carcinoma: Analysis From the International Marker Consortium for Renal Cancer (INMARC)
inferred← citeshttps://doi.org/10.1016/j.urolonc.2020.04.031openalex-snapshot
Bone metastasis is associated with poor prognosis in metastatic papillary renal cell carcinoma patients treated with first agent angiogenesis inhibitors
inferred← citeshttps://doi.org/10.1016/j.urolonc.2021.04.013openalex-snapshot
Papillary renal cell carcinoma: Review
inferred← citeshttps://doi.org/10.1038/s41598-020-78174-9openalex-snapshot
The effect of the papillary renal cell carcinoma subtype on oncological outcomes
inferred← citeshttps://doi.org/10.1038/s41598-021-91217-zopenalex-snapshot
The first competing risk survival nomogram in patients with papillary renal cell carcinoma
inferred← citeshttps://doi.org/10.1080/0284186x.2018.1537505openalex-snapshot
Metastatic papillary renal cell carcinoma in the era of targeted therapy – a retrospective study from three European academic centres
inferred← citeshttps://doi.org/10.1080/0284186x.2022.2119100openalex-snapshot
Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma
inferred← citeshttps://doi.org/10.1097/md.0000000000016309openalex-snapshot
A comparison of the prognosis of papillary and clear cell renal cell carcinoma
inferred← citeshttps://doi.org/10.1097/ppo.0000000000000468openalex-snapshot
Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.1101/2025.01.24.632989openalex-snapshot
Identification of a novel papillary renal cell carcinoma molecular subtype characterized by HIF-pathway over-activation
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-18-1189openalex-snapshot
First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity
inferred← citeshttps://doi.org/10.1186/s12885-021-08139-2openalex-snapshot
Construction autophagy-related prognostic risk signature combined with clinicopathological validation analysis for survival prediction of kidney renal papillary cell carcinoma patients
inferred← citeshttps://doi.org/10.1186/s12894-023-01218-5openalex-snapshot
Bioinformatic analysis highlights SNHG6 as a putative prognostic biomarker for kidney renal papillary cell carcinoma
inferred← citeshttps://doi.org/10.1186/s12916-019-1419-1openalex-snapshot
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort
inferred← citeshttps://doi.org/10.1200/jco.2018.79.0147openalex-snapshot
Prognostication in Kidney Cancer: Recent Advances and Future Directions
inferred← citeshttps://doi.org/10.17998/jlc.2023.11.05openalex-snapshot
Metastatic papillary renal cell carcinoma with portal vein tumor thrombosis confirmed on blind liver biopsy
inferred← citeshttps://doi.org/10.21037/atm-20-3750openalex-snapshot
Prognostic models in papillary renal cell carcinoma
inferred← citeshttps://doi.org/10.21037/atm-20-7009openalex-snapshot
Renal cell carcinoma with non-clear cell histology or sarcomatoid differentiation: recent insight in an unmet clinical need
inferred← citeshttps://doi.org/10.2217/fon-2020-0725openalex-snapshot
Treatment Patterns, Outcomes and Clinical Characteristics in Advanced Renal Cell Carcinoma: a Real-World US Study
inferred← citeshttps://doi.org/10.3233/kca-190058openalex-snapshot
A Review of Papillary Renal Cell Carcinoma and MET Inhibitors
inferred← citeshttps://doi.org/10.3389/fonc.2024.1378087openalex-snapshot
A pan-cancer analysis of EphA family gene expression and its association with prognosis, tumor microenvironment, and therapeutic targets
inferred← citeshttps://doi.org/10.3389/fsurg.2021.763271openalex-snapshot
Treatment and Outcome of Metastatic Renal Cell Carcinoma With Sarcomatoid Differentiation: A Single-Center, Real-World Analysis of Retrospective Data
inferred← citeshttps://doi.org/10.3390/cancers14246064openalex-snapshot
Divulging a Pleiotropic Role of Succinate Receptor SUCNR1 in Renal Cell Carcinoma Microenvironment
inferred← citeshttps://doi.org/10.3390/medicines7080044openalex-snapshot
Genetic Alterations in Renal Cancers: Identification of The Mechanisms Underlying Cancer Initiation and Progression and of Therapeutic Targets
inferred← citeshttps://doi.org/10.4274/mirt.galenos.2024.02259openalex-snapshot
The Utility of 18F-FDG PET/CT in Detecting Multiple Metastases in Papillary Renal Cell Carcinoma
inferred← citeshttps://doi.org/10.5489/cuaj.9041openalex-snapshot
2024 CUA-KCRNC Expert Report: Management of non-clear cell renal cell carcinoma
inferred← citeshttps://doi.org/10.5772/intechopen.85931openalex-snapshot
Medical Management of Renal Cell Cancer
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.